PARP1 and neoplasm: A selective and orally bioavailable inhibitor of p97, CB-5083 led to marked increase of talazoparib sensitivity in a patient-derived tumor organoid model derived from a patient with BRCA1 mutated TNBC, suggesting the potential therapeutic effect of combined treatment of p97 and PARP inhibitors in cancer patients [60].